Theranostics for Triple-Negative Breast Cancer.
Hye Ryeon ChoiKwangsoon KimPublished in: Diagnostics (Basel, Switzerland) (2023)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.
Keyphrases
- poor prognosis
- drug delivery
- end stage renal disease
- long non coding rna
- cancer therapy
- photodynamic therapy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- dna damage
- prognostic factors
- peritoneal dialysis
- computed tomography
- single cell
- patient reported outcomes
- mesenchymal stem cells
- young adults
- dna repair
- fatty acid
- dna binding
- fluorescence imaging
- replacement therapy
- walled carbon nanotubes